By admin 
CureSearch for Children’s Cancer, a leading national non-profit foundation, has officially announced the recipient of its prestigious 2026 Catapult Award, marking a significant milestone in the fight against high-risk pediatric solid tumors. Dr. Robbie Majzner of the Dana-Farber Cancer Institute has been awarded a $2 million grant to spearhead a Phase I clinical trial for a next-generation CAR T-cell therapy specifically engineered for children and young adults with relapsed or refractory neuroblastoma. This investment, co-funded by the Jeff Gordon Children’s Foundation, aims to bridge the "valley of death"—the precarious gap between laboratory discovery and clinical application—by providing the necessary resources to move a promising biological innovation into the hands of clinicians and patients.
Neuroblastoma remains one of the most formidable challenges in pediatric oncology. As the most common extracranial solid tumor in children, it originates in the sympathetic nervous system, typically in the adrenal glands, but often spreads to the bone marrow, liver, and lymph nodes by the time of diagnosis. Despite decades of advancement in multimodal therapies involving high-dose chemotherapy, surgical resection, radiation, and autologous stem cell transplantation, the prognosis for high-risk patients remains sobering. Statistics indicate that neuroblastoma accounts for more than 10% of all childhood cancer deaths, and for those with high-risk or relapsed disease, five-year survival rates frequently languish below 50%. The introduction of this new CAR T-cell trial represents a critical pivot toward precision immunotherapy for a patient population that has historically exhausted standard-of-care options.
The Evolution of Immunotherapy in Pediatric Oncology
The development of Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment landscape for hematologic malignancies, such as B-cell acute lymphoblastic leukemia (ALL). By extracting a patient’s own T cells and genetically modifying them to express receptors that recognize specific proteins on cancer cells, scientists have achieved remarkable remission rates in blood-borne cancers. However, translating this success to solid tumors, including neuroblastoma, has proven exceptionally difficult.
Solid tumors present a hostile microenvironment that can physically shield cancer cells and chemically suppress the immune response. A primary obstacle in neuroblastoma treatment has been "T-cell exhaustion," a state where the engineered immune cells become dysfunctional and lose their ability to proliferate or kill cancer cells after initial exposure to the tumor. Traditional CAR T-cell designs often fail to maintain a sustained attack, leading to disease recurrence. Dr. Majzner’s research focuses specifically on overcoming these biological hurdles through structural innovations in the CAR molecule itself.
Technical Innovation: The ZAP70 Signaling Architecture
The therapeutic approach funded by the Catapult Award targets GD2, a disialoganglioside highly expressed on the surface of neuroblastoma cells. While GD2 has long been a target for monoclonal antibody therapies, Dr. Majzner’s team has introduced a sophisticated modification to the CAR signaling domain. By incorporating a novel signaling protein known as ZAP70, the researchers believe they can mimic the natural signaling pathways of a T cell more effectively than previous generations of CAR constructs.
In preclinical models, this "next-generation" CAR architecture demonstrated a superior ability to resist exhaustion. By modulating the intensity and duration of the signal sent to the T cell upon contact with the tumor, the ZAP70-integrated cells remained active longer and showed enhanced persistence in the body. Furthermore, the preclinical data suggested an improved safety profile, a critical consideration given the potential for "off-target" toxicities—such as neurotoxicity or cytokine release syndrome—that can occur when the immune system is aggressively stimulated. This Phase I trial will be the first time this specific ZAP70-based architecture is tested in human subjects, prioritizing safety and dose-escalation protocols to determine the optimal therapeutic window.
Bridging the Research Gap: The Role of the Catapult Award
The CureSearch Catapult Award is strategically designed to address the unique economic and regulatory hurdles of pediatric drug development. Unlike adult oncology, where large pharmaceutical companies often invest heavily in early-stage trials due to the massive market potential, pediatric cancer research frequently relies on philanthropic intervention. Because childhood cancers are considered "rare diseases" by traditional market standards, the financial incentive for private industry to fund early-phase clinical trials is often lacking.
By providing $2 million in direct funding, CureSearch and the Jeff Gordon Children’s Foundation are de-risking the project, allowing Dr. Majzner to gather the essential human data required to eventually attract larger-scale investment or federal support. This funding model is essential for ensuring that academic breakthroughs do not languish in the laboratory. Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, emphasized that the Catapult Award is specifically tailored for "high-potential research" that has already shown efficacy in the lab but requires a final push to reach the clinical stage.
Chronology and Trial Implementation
The timeline for the Phase I trial is expected to commence following the formalization of the 2026 grant cycle. The Dana-Farber Cancer Institute, a world-renowned leader in pediatric cancer care and research, will serve as the primary site for the study. The trial will follow a traditional Phase I structure, focusing on a small cohort of children and young adults with relapsed or refractory neuroblastoma—patients whose cancer has returned after treatment or failed to respond to initial therapies.
The primary objectives of the study include:
- Safety and Tolerability: Monitoring patients for adverse effects related to the infusion of the modified T cells.
- Dose Determination: Identifying the maximum tolerated dose (MTD) of the CAR T cells.
- Cellular Persistence: Measuring how long the engineered cells remain detectable in the patient’s bloodstream and tumor sites.
- Preliminary Efficacy: Observing the anti-tumor response and changes in tumor markers.
If the Phase I results prove successful, it will set the stage for Phase II trials, which would involve a larger patient population to more definitively measure the treatment’s effectiveness compared to current standard therapies.
Collaborative Support and Organizational Perspectives
The partnership between CureSearch and the Jeff Gordon Children’s Foundation underscores a growing trend of collaborative philanthropy in the medical sector. By pooling resources, these organizations can fund larger, more impactful grants that single entities might struggle to sustain. Jeff Gordon, the NASCAR champion and founder of the eponymous foundation, has long been a vocal advocate for pediatric cancer research, focusing on the need for less toxic and more effective treatments.
Dr. Robbie Majzner, the recipient of the award, noted the transformative nature of this support. "Current GD2 CAR T cells only work in patients with small amounts of disease," Dr. Majzner explained. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most. The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
His sentiment is echoed by the broader scientific community, which views the Majzner lab’s work as a potential blueprint for treating other "cold" solid tumors. If the ZAP70 modification proves effective in neuroblastoma, the same technology could theoretically be adapted for other pediatric cancers, such as osteosarcoma or Ewing sarcoma, as well as adult cancers like melanoma and small cell lung cancer.
Broader Implications for Pediatric Medicine
The implications of this trial extend beyond the immediate cohort of neuroblastoma patients. The success of this study would represent a major victory for the field of synthetic biology and cellular engineering. It would validate the theory that "tuning" the internal signaling of immune cells can overcome the environmental resistance of solid tumors.
Furthermore, the focus on "relapsed and refractory" cases addresses the most urgent need in oncology. While initial cure rates for many childhood cancers have improved over the last half-century, the survival rate for those who suffer a relapse has remained largely stagnant. Innovative therapies like Dr. Majzner’s CAR T-cell approach offer a beacon of hope for families who have been told that no further conventional options exist.
As the 2026 trial approaches, the pediatric oncology community remains cautiously optimistic. The transition from bench to bedside is a rigorous process fraught with scientific and regulatory challenges, but the backing of the CureSearch Catapult Award ensures that this specific line of inquiry has the best possible chance of success. By investing in bold, high-risk, high-reward science, CureSearch continues to redefine the boundaries of what is possible in the treatment of childhood cancer, moving closer to a future where every child diagnosed with neuroblastoma has a viable path to long-term survival.
